Category Archives: Cancer Treatment

Tempus a Chicago-Base Company gets Unicorn status funding

The Co-founder and CEO of Tempus Eric Lefkofsky are on a mission with his new technology and his operating system to collect clinical and molecular data from new patients and those who have been suffering from cancer and other life-threatening diseases. The goal is to improve the health care system and to have the necessary information to better treatment options.

Tempus is a Chicago-base technology company that recently achieved the ‘Unicorn’ status with $80M in new funding from a group of new and existing investors. There is a big achievement and they will use their funding to keep expanding and researching. There are not many companies today with that status.

The CEO and Co-founder of Tempus Eric Lefkofsky have a goal and is to improve patient outcomes from treatments of others. In fact, he wishes to provide physicians, oncologists, pathologists, researchers and also insurance companies with a system that they can use to help better and efficiently patients with cancer and other diseases, therefore, using this technology the health care system will be more precise and accessible to all.

However, Tempus has a big challenge and that is to provide Cancer Centers, hospitals, community centers and private clinics with this operating system and give the tools to doctors to fight the battle against cancer. In the meantime, this sequencing of clinical and molecular data will be inexpensive and easy to use in an effort to treat every patient with different illnesses better than ever.

Eric Lefkofsky has the experience with technology and he knows that the health care system has to improve. Consequently, doctors and researchers need the tools to gather information with a system that collects big data, using artificial intelligence and advanced molecular analysis.

Tempus has built the operating system to battle cancer. Medical trials and clinical records are not sufficient. This technology collects data from all patients, the drugs they are taking, which ones are giving results and which ones are not. This operating system has to be in every clinic, hospital and cancer centers.

Eric Lefkofsky info:

Living & Leading by Example: Dr. Clay Siegall

We should all strive to lead the most progressive life as we can. Unfortunately, life tends to throw us all a few curb balls here and there. Disease and illness just so happens to be a pitfall in life as well as a curb ball. Cancer needs no introduction because it has reaped havoc for so many people. Past cancer-treatment medications could only do so much because of the lack of information. Thanks to living in the 21st century, we have an abundance of information at our disposal and medical doctors have certainly exploited this information for the greater good of society.

Seattle Genetics is the cream-of-the-crop when it comes to fighting cancer. This oncology company has made an impact on cancer research, and it has made an impact in people’s lives. Dr. Clay Siegall is the man in charge here, and he has demonstrated excellence throughout his long career. Many of his constituents refer to him as being a doctor, a businessman, and entrepreneur and a scientist. The guy literally has a fantastic educational background. Dr. Siegall specializes in the fields of genetics and zoology. On the other hand, his business-savvy sense has helped to takse the company to an all-new level. By securing multiple licensing for the company’s top drug, Dr. Siegall has given the “green light” on distributing the drugs to foreign nations. Yes, there are up to 65 nations that use Seattle Genetics’ ADCETRIS drug.

In addition to this high-quality deed, Dr. Siegall does a great job of bringing in extra income via private fundraising. In total, he has generated over $1 billion by doing so and that’s a fact. Most of this extra income goes right back into the program itself. All in all, Dr. Clay Siegall is simply leading by example because he’s setting new trends that were once never seen, and he has changed the status quo.

Eric Lefkofsky Has Made A Difference In The Way Cancer Is Treated

Cancer is a serious disease and affects a large portion of adults living in the United States. Eric Lefkofsky believes the answer is in data-enabled precision medicine and it was for this reason he co-founded Tempus. There has been a lot of talk about electronic health records in the world of medicine but the modern technology in the field is not as advanced as it could be. Tempus comes into play with their platform to effectively analyze all the data of a patient. The molecular and clinical data is crucial in the way cancer is treated. One the structured data is readily available to the medical world the treatment and care received by cancer patients can be advanced.

Human genome sequencing is used to gather an individual’s genomic information. This process is not new but advancements in technology and science have substantially lowered the once astronomical cost. Eric Lefkofsky uses this data because it holds the secrets of the human genes. When this data is combined with the molecular and clinical data of a patient it makes fighting many diseases including cancer easier. The more data that is analyzed the clearer the picture becomes to the researchers. Through the information provided by Tempus and other technological research facilities physicians will eventually be able to make a specific pairing between a cancer patient and the treatment that will produce the best results for their exact situation. Ineffective treatments can be eliminated and the more effective treatments further researched.

The journey taken by Eric Lefkofsky before Tempus began in 1969. His life began in Michigan and his accomplishments already rival the success of a lifetime. Shortly after he had completed his education it was obvious he was a major power player. Instead of going into the field of law as he initially intended he became involved in the revolution of the For more info about us: click here.

Eric Lefkofsky lives his life near Chicago and devotes a portion of his time helping local charities. He serves on the board for several of Chicago’s hospitals, museums, and theatres. He is an adjunct professor and has progressed the treatment of cancer through his passion, expertise, and dedication.

Eric Lefkofsky sees future of cancer treatment in genomic data

Eric Lefkofsky has become one of the nation’s most widely respected tech entrepreneurs. After founding Groupon, a company that allows individuals to become part of groups eligible for deep discounts on everything from pizza to hotel rooms, he went on to have a successful second career developing a string of successful startups.

But then, in 2013, Lefkofsky’s wife got a terrible diagnosis. She had advanced breast cancer. The Lefkofsky’s both put their heads down and charged the disease full-on. Over the course of the next year, Lefkofsky accompanied his wife to dozens of appointments. In the end, his wife was cured of the disease and, today, is a cancer survivor.

But Lefkofksy left the process of cancer treatment with the deep impression that things were not all well with the state of modern oncology. He noted that many of the oncologists who saw his wife did not have ready access to the best data and analytics, crucial tools that could provide key information to the treatment process. Lefkofsky decided to research ways in which all of the sources of oncologically relevant data could be put into the hands of oncologist, in ways that were digestible and informative to the decision makers.

In 2016 Eric Lefkofsky founded Tempus, a company dedicated to the provision of oncologists with key intelligence, which is mined from a vast number of primary data sources. The idea behind Tempus is to create a sort of on-demand meta-study capability, where interesting questions that oncologists may have regarding patient cohorts  treatment regimes can be answered in real time.

One of the most potent sources of largely untapped data is the human genome itself. Tempus is creating a system that will be able to use the genome of cancer patients to find relationships between genetics, comorbid conditions and data from studies and how these things affect treatment outcomes. Within the next decade, Lefkofsky sees the rapidly diminishing cost of sequencing the human genome as being the main driver of medical advances, with practically every future patient cohort having their entire genome completely sequenced. This will provide a level of understanding previously never imagined.

To learn more visit @: